Cardiac MRI will be used to assess whether Dapagliflozin regresses LV mass more than placebo does over a one year treatment period. If it does, this would strongly suggest that Dapagliflozin will reduce CV events especially in the 44% of patients with type 2 diabetes who have LVH despite a controlled blood pressure.